Skip to main content
GutCited

Lactobacillus gasseri para Helicobacter pylori Infection

B

Three RCTs show L. gasseri LG21 suppresses H. pylori load and improves eradication rates when combined with standard triple therapy. Also improves GERD symptoms.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dlactobacillus\u002Dgasseri\u0026condition\u003Dh\u002Dpylori'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

B

Conclusão

Three RCTs show L. gasseri LG21 suppresses H. pylori load and improves eradication rates when combined with standard triple therapy. Also improves GERD symptoms.

Key Study Findings

In Vitro
Lactobacillus gasseri suppresses the Helicobacter pylori-induced expression of the proliferation-associated factors HBEGF and TGF-α in …
Dose: None vs: H. pylori infection without lactobacilli Outcome: ADAM17, HBEGF, TGF-alpha expression Efeito: None None

População: AGS gastric epithelial cells and mouse model

In Vitro
Lactobacillus gasseri Suppresses the Helicobacter pylori-Induced Hummingbird Phenotype by Inhibiting CagA Phosphorylation and SHP-2 Interaction.
Dose: None vs: CagA-expressing AGS cells without L. gasseri Outcome: Suppression of CagA phosphorylation (hummingbird) Efeito: None None

População: Human gastric AGS cell line with H. pylori CagA

In Vitro
The modulatory effect of Lactobacillus gasseri ATCC 33323 on autophagy induced by extracellular vesicles of …
Dose: 50 μg/ml vs: None Outcome: Inflammatory markers Efeito: None None

População: None

Other
Effect of Lactobacillus gasseri BIO6369 and Lacticaseibacillus rhamnosus BIO5326 on Gastric Carcinogenesis Induced by Helicobacter …
Dose: None vs: None Outcome: Inflammatory markers Efeito: None None

População: Cancer patients

Other
Two novel lactic acid bacteria, Limosilactobacillus fermentum MN-LF23 and Lactobacillus gasseri MN-LG80, inhibited Helicobacter pylori …
Dose: None vs: None Outcome: H. pylori abundance reduction Efeito: None None

População: H. pylori-infected C57BL/6 mice

Case-Control n=178
Oral and gastric microbiome in relation to gastric intestinal metaplasia.
Dose: None vs: None Outcome: Oral/gastric microbiome associations with IM Efeito: None None

População: Gastric intestinal metaplasia cases and matched controls

Key Statistics

3

Estudos

350

Participantes

Positive

B

Nota

Referenced Papers

International journal of … 2022 59 citações
Comparative immunology, microbiology … 2019 72 citações
Probiotics and antimicrobial … 2010 9 citações

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Dosagens Comumente Utilizadas

general:
1-10 billion CFU/day
gerdsupport:
1-5 billion CFU/day
hpylorisupport:
100 million CFU/day (LG21 strain, yogurt form) for 8-12 weeks

Limite superior: Well-tolerated up to 10 billion CFU/day in clinical trials

Dosagens Estudadas em Pesquisas

Dosagem Duração Efeito N
None -- Positive --
None -- Positive --
50 μg/ml -- Mixed --
None -- Positive --
None -- Positive --
None -- Neutral 178
None -- Positive --
1 g -- Positive --

Melhor horário: Before meals or with meals; yogurt form taken with food

Safety & Side Effects

Efeitos Colaterais Relatados

  • Mild gas during initial use
  • Occasional loose stools
  • Rare abdominal discomfort
  • Very rare: bacteremia in immunocompromised individuals

Interações Conhecidas

  • Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
  • Proton pump inhibitors (altered gastric pH may affect colonization)
  • Immunosuppressants (theoretical risk in immunocompromised patients)

Ingestão máxima tolerável: Well-tolerated up to 10 billion CFU/day in clinical trials

Consulte sempre o seu profissional de saúde antes de iniciar qualquer suplemento.Sempre consulte seu profissional de saúde antes de iniciar qualquer suplemento.

Frequently Asked Questions

Does Lactobacillus gasseri help with Helicobacter pylori Infection?
Based on 3 studies with 350 participants, there is moderate evidence from clinical studies that Lactobacillus gasseri may support Helicobacter pylori Infection management. Our evidence grade is B (Good Evidence).
How much Lactobacillus gasseri should I take for Helicobacter pylori Infection?
Studies have used various dosages. A commonly studied range is 1-10 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Lactobacillus gasseri?
Reported side effects may include Mild gas during initial use, Occasional loose stools, Rare abdominal discomfort, Very rare: bacteremia in immunocompromised individuals. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Lactobacillus gasseri and Helicobacter pylori Infection?
We rate the evidence as Grade B (Good Evidence). This rating is based on 3 peer-reviewed studies with 350 total participants. The overall direction of effect is positive.

Related Evidence

Outros ingredientes para Helicobacter pylori Infection

Lactobacillus gasseri para outras condições

Aviso Legal da FDA: Estas declarações não foram avaliadas pela Food and Drug Administration. Os produtos e informações neste site não se destinam a diagnosticar, tratar, curar ou prevenir qualquer doença. As notas de evidência apresentadas são baseadas em nossa análise de pesquisas revisadas por pares publicadas e não constituem aconselhamento médico. Sempre consulte seu profissional de saúde antes de iniciar qualquer regime de suplementação.